Bespoke Extracts (BSPK) Cash from Operations (2011 - 2025)
Bespoke Extracts (BSPK) reported Cash from Operations of 19620.0 for Q3 2025, up 30.78% on a YoY basis from 15001.85 in Q3 2024, and up 36.71% sequentially from 31002.0 in Q2 2025.
Bespoke Extracts (BSPK) Cash from Operations (2011 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 15 years of Cash from Operations data on file, last reported at 19620.0 in Q3 2025.
- For the quarter ending Q3 2025, Cash from Operations rose 30.78% year-over-year to 19620.0; the trailing twelve-month figure through Sep 2025 stood at 259702.0 (down 49.74% YoY), and the FY2024 full-year result was 289802.0, up 30.2% from the prior year.
- Cash from Operations improved to 19620.0 in Q3 2025, from 31002.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 239793.0 in Q2 2022 to a low of 633423.0 in Q3 2021.
- A 5-year average of 161185.0 and a median of 97191.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations surged 101.12% in 2023 and sank 588.69% in 2024, its largest moves.
- Tracing BSPK's Cash from Operations over 5 years: stood at 29882.0 in 2021, then tumbled by 547.24% to 193407.0 in 2022, then jumped by 89.78% to 19768.0 in 2023, then slumped by 588.69% to 136140.0 in 2024, then soared by 85.59% to 19620.0 in 2025.
- Business Quant data shows BSPK's Cash from Operations at 19620.0 in Q3 2025, 31002.0 in Q2 2025, and 72940.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | -19,620.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -19,620.00 |
| Sep 30, 2025 | -19,620.00 |
| Jun 30, 2025 | -31,002.00 |
| Jun 30, 2025 | -31,002.00 |
| Mar 31, 2025 | -72,940.00 |
| Mar 31, 2025 | -72,940.00 |
| Dec 31, 2024 | -136,140.00 |
| Dec 31, 2024 | -136,140.00 |
| Sep 30, 2024 | -28,346.00 |
| Sep 30, 2024 | -28,346.00 |
| Jun 30, 2024 | -28,125.00 |
| Jun 30, 2024 | -28,125.00 |
| Mar 31, 2024 | -97,191.00 |
| Mar 31, 2024 | -97,191.00 |
| Dec 31, 2023 | -19,768.00 |
| Dec 31, 2023 | -19,768.00 |
| Sep 30, 2023 | 7,010.00 |
| Sep 30, 2023 | 7,010.00 |
| Jun 30, 2023 | -195,372.00 |
| Jun 30, 2023 | -195,372.00 |